Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company specializing in the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platforms include PolyXen™, which enhances the half-life and other pharmacological properties of biologic drugs.
Xenetic’s lead investigational product candidates comprise the FDA orphan-designated oncology therapeutic Sodium Cridanimod for progesterone receptor-negative endometrial cancer, and a polysialylated form of erythropoietin for treating anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also collaborating with Shire PLC (formerly Baxalta, Baxter Incorporated, and Baxter Healthcare) to develop polysialylated blood coagulation factors, including a next-generation Factor VIII.
In the immune-oncology space, Xenetic is advancing XCART, a personalized CAR T platform technology, and the DNase platform aimed at improving existing treatments by targeting neutrophil extracellular traps (NETs) implicated in cancer progression and resistance. The company is working towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Recent financial updates reveal that Xenetic ended Q2 2023 with approximately $10.7 million in cash and no debt. The company reported a net loss of $1.1 million for Q3 2023 and continued to secure strategic collaborations and advance its DNase-based oncology program.
Xenetic Biosciences (NASDAQ:XBIO) announced the appointment of Dr. Jonathan Spicer to its Scientific Advisory Board, enhancing its expertise in the role of neutrophil extracellular traps (NETs) in cancer biology. Dr. Spicer, an expert in neoadjuvant immunotherapy for lung cancer, will support the advancement of the Company's DNase platform, which aims to improve cancer treatment outcomes by targeting NETs. This collaboration is pivotal as Xenetic progresses towards a planned Phase 1 study, indicating potential growth in its innovative oncology technologies.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q3 2022, highlighting progress in its DNase-based oncology platform targeting hard-to-treat cancers. The company ended the quarter with $13.8 million in cash. Notably, net loss was approximately $0.8 million, with R&D expenses down 48.9% to $0.4 million. The company also received $0.4 million in royalties, reflecting an 18.6% increase year-over-year. Xenetic remains focused on advancing its DNase program and collaborations aimed at enhancing cancer therapies.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.
Xenetic Biosciences (NASDAQ: XBIO) announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung, a leading expert in cancers of the liver, bile duct, and pancreas, brings extensive clinical and research experience, aiming to guide the company’s DNase-based oncology platform. His leadership at the University of Virginia and participation in numerous academic surgical organizations positions him to contribute significantly to Xenetic’s development strategies. This appointment is part of the company’s commitment to advancing innovative immune-oncology technologies to address unmet medical needs in cancer treatment.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY, from September 12-14, 2022. Jeffrey F. Eisenberg, the CEO, will present at the event, which will also feature virtual one-on-one meetings for registered investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET, archived for 90 days. The Company is advancing innovative immune-oncology technologies, particularly for hard-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) reported its second quarter 2022 results, highlighting a significant in-licensing deal that expands its oncology pipeline with a focus on DNase-based therapies. The company aims to advance its DNase program towards a Phase 1 study targeting pancreatic carcinoma and other advanced solid tumors. Financially, Xenetic ended the quarter with $14.9 million in cash but posted a net loss of approximately $2.7 million. R&D expenses surged by 296.1% due to investments in the new DNase platform.
Xenetic Biosciences (NASDAQ: XBIO) and VolitionRx Limited (NYSE AMERICAN: VNRX) announced a collaboration to develop Neutrophil Extracellular Traps (NETs) targeted, adoptive cell therapies for cancer treatment. The program aims to evaluate the integration of Volition's Nu.Q® NETs Test with Xenetic's DNase-Armored CAR T platform to potentially address multiple solid tumor types. Volition will fund the research, sharing proceeds from commercialization. The collaboration highlights both companies' commitment to innovative cancer therapies and reflects Xenetic's recent acquisition of the DNase platform.
Xenetic Biosciences (NASDAQ: XBIO) has entered into a manufacturing agreement with Catalent Pharma Solutions to advance its DNase-based oncology platform aimed at enhancing treatment outcomes for solid tumors, including pancreatic carcinoma. The agreement facilitates cGMP manufacturing for Human DNase I, supporting the company's planned first-in-human study combining DNase with immune checkpoint inhibitors or chemotherapy. This collaboration signifies a strategic step towards developing innovative therapies for difficult-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) will host a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a moderated roundtable with the company's leadership and surgical oncology expert, Allan Tsung, MD. The discussion will cover their innovative DNase oncology platform targeting solid tumors and the personalized CAR T platform for B-Cell lymphomas. Investors can submit questions during the event. A live webcast will be available, and a replay will be accessible for 90 days after the event.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) will participate in a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a roundtable with CEO Jeffrey Eisenberg, Chief Scientific Officer Curtis Lockshin, and oncology expert Allan Tsung, MD. They will discuss Xenetic's DNase-based oncology platform, focusing on how it targets Neutrophil Extracellular Traps (NETs) in cancer treatment. A live video webcast will be available on the Company's website, and questions from the audience will be addressed during the session.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What is Xenetic Biosciences' main focus?
What are the primary platforms used by Xenetic Biosciences?
What are Xenetic Biosciences' lead investigational products?
Who are Xenetic Biosciences' key partners?
What is the focus of Xenetic's DNase platform?
What are the company's recent financial highlights?
What is the goal of Xenetic's XCART technology?
What are the company’s plans for its DNase-based oncology program?
How does the PolyXen™ platform benefit biologic drugs?
Where can I find more information about Xenetic Biosciences?
